| Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors F Pecci, S Nakazawa, B Ricciuti, G Harada, JK Lee, JV Alessi, ... Cancer Discovery, OF1-OF17, 2024 | | 2024 |
| Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer M Ambrosini, B Rousseau, P Manca, O Artz, A Marabelle, T André, ... Annals of Oncology 35 (7), 643-655, 2024 | 1 | 2024 |
| Pathological complete response (pCR) association with a novel homologous recombination deficiency HRD signature (HRDsig) in patients with triple-negative breast cancer (TNBC … T Gupta, RP Graf, AB Schrock, R Madison, JS Ross, MA Levy, ... Journal of Clinical Oncology 42 (16_suppl), 591-591, 2024 | | 2024 |
| Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors. D Liu, RB Keller-Evans, AB Schrock, AE Drilon, J Jee, BT Li Journal of Clinical Oncology 42 (16_suppl), 3129-3129, 2024 | | 2024 |
| Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world data MJ Emmett, JCF Quintanilha, RP Graf, G Li, H Tukachinsky, AB Schrock, ... ESMO Real World Data and Digital Oncology 4, 100036, 2024 | | 2024 |
| Liquid biopsy‐based circulating tumour (ct) DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results DA Mata, JK Lee, V Shanmugam, CB Marcus, AB Schrock, EA Williams, ... Histopathology 84 (7), 1224-1237, 2024 | | 2024 |
| Abstract PO2-16-03: ESR1 genomic alterations (GAs) and coexistent putative resistance alterations in comprehensive genomic profiling (CGP) of metastatic breast cancer (MBC) H McArthur, H Tukachinsky, A Schrock, R Madison, O Holmes, ... Cancer Research 84 (9_Supplement), PO2-16-03-PO2-16-03, 2024 | | 2024 |
| Abstract PO2-16-05: ESR1 mutations (ESR1mut) in HR (+) HER2 (-) patients with metastatic breast cancer (MBC): prevalence along treatment course and predictive value for … M Bhave, J Quintanilha, R Graf, T Scott, H Tukachinsky, G Li, A Schrock, ... Cancer Research 84 (9_Supplement), PO2-16-05-PO2-16-05, 2024 | | 2024 |
| RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer H Singh, P Sahgal, K Kapner, SM Corsello, H Gupta, R Gujrathi, YY Li, ... Clinical Cancer Research 30 (8), 1669-1684, 2024 | | 2024 |
| Genomic profiling of KRAS and EGFR-altered non-squamous non-small cell lung cancer reveal ancestry-specific co-alterations with therapeutic implications SD Sisoudiya, AA Houle, TM Fernando, TR Wilson, JL Schutzman, JK Lee, ... Cancer Research 84 (6_Supplement), 6120-6120, 2024 | | 2024 |
| Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non–Small-Cell Lung Cancer J Yorio, KT Lofgren, JK Lee, K Tolba, GR Oxnard, AB Schrock, ... JCO Precision Oncology 8, e2300292, 2024 | 1 | 2024 |
| Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC PC Mack, RB Keller-Evans, G Li, KT Lofgren, AB Schrock, SE Trabucco, ... The Oncologist, oyae028, 2024 | | 2024 |
| Circulating tumor DNA enables sensitive detection of actionable gene fusions and rearrangements across cancer types PM Kasi, JK Lee, LW Pasquina, B Decker, P Vanden Borre, DC Pavlick, ... Clinical Cancer Research 30 (4), 836-848, 2024 | 9 | 2024 |
| Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma L Burns, H Tukachinsky, K Raskina, RSP Huang, AB Schrock, J Sands, ... Lung Cancer 188, 107454, 2024 | | 2024 |
| The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced Prostate Cancer WH Jin, L Zhang, R Graf, K Raskina, H Tukachinsky, RSP Huang, ... Clinical genitourinary cancer 22 (1), e163-e169. e1, 2024 | 1 | 2024 |
| Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib JK Rotow, JK Lee, RW Madison, GR Oxnard, PA Jänne, AB Schrock Journal of Thoracic Oncology 19 (2), 227-239, 2024 | 8 | 2024 |
| Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal … CM Parseghian, JK Lee, J Quintanilha, AB Schrock, R Graf, L Pasquina, ... Journal of Clinical Oncology 42 (3_suppl), 199-199, 2024 | | 2024 |
| POLE variant phenotypic classification to enable identification of patients with colorectal cancer (CRC) who may benefit from immune checkpoint inhibition (ICI). RB Keller, Z Fleischmann, S Sivakumar, R Sharaf, T Janovitz, AB Schrock, ... Journal of Clinical Oncology 42 (3_suppl), 194-194, 2024 | | 2024 |
| Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study G Randon, Y Nakamura, R Yaeger, S Lonardi, C Cremolini, E Elez, ... Clinical Cancer Research 30 (2), 436-443, 2024 | 3 | 2024 |
| Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment A Russo, JK Lee, LW Pasquina, M Del Re, HH Dilks, K Murugesan, ... JCO Precision Oncology 8, e2300535, 2024 | 1 | 2024 |
